Pancreatic adenocarcinoma (PDAC) is defined by a number of hallmarks: high rate of KRAS activating and TP53 inactivating mutations, propensity for local and distant invasion, desmoplasia resulting in a hypovascular and hypoxic microenvironment, reprograming of cellular metabolism, and tumor immune invasion.
The intrinsic factors for metabolic plasticity induce abnormal mitochondrial metabolism and enhance glycolysis, with alterations in glutamine and lipid metabolism. The extrinsic factors induce cancer cells to reprogram their metabolic pathway and hijack stromal cells (mainly cancer-associated fibroblasts and immunocytes) to communicate, thereby adapting to metabolic stress. This provides a strong rationale for novel therapies that target the mitochondrial metabolism. 8 9, 10 Drug inhibition of the tumor cell TCA cycle substantially reduces the mitochondrial export of anabolic intermediates, including those essential to nucleotide synthesis. Compromised nucleotide synthesis is expected to substantially interfere with the efficiency of the DNA damage response. In turn, the DNA damage response is necessary for tumor cells to resist and recover from the effects of the active FOLFIRINOX components.
Figure 1. CPI-613 inhibits mitochondrial metabolism selectively in tumor cells

Pharmacokinetics
CPI-613 (6,8-bis-benzylsulfanyloctanoic acid) is rapidly converted within minutes by beta-oxidation to the active metabolite (4,6-bis-benzylsulfanyloctanoic acid) (CPI-2850). In model systems, CPI-2850 is similar in potency to CPI-613. In study 57112, the pharmacokinetics of CPI-613 and the metabolite CPI-2850 were evaluated in 18 patients treated at 500 mg/m 2 and in 2 patients treated at 1000 mg/m 2 , following either a short (14-20 mins) or long IV infusion 2hrs). Plasma samples for PK analysis were collected pre-dosing with CPI-613 and at approximately 5, 30, 60, 90 mins, 2, 4, 6, 8, 24 and 72 hrs post infusion.
Non-compartmental PK data analysis (NCA) was conducted using a validated installation of WinNonLin v6.4 (Pharsight Corp, CA). The PK parameters of CPI-613 and CPI-2850, together with their summary statistics are presented in Table 1 . The observed pharmacokinetics of CPI-613 are consistent with the results of a prior escalating dose Phase I study in patients with advanced hematologic malignancies.
11
As shown in Figure 2 , CPI-613 and CPI-2850 follow a bi-phasic disposition profile with the emergence of secondary peaks best seen in the levels of CPI-613 in graph B during the elimination phase, indicative of possible entero-hepatic recirculation. The only major metabolite identified in plasma was CPI-2850 and no glucuronide and sulfoxide metabolites were observed. The biotransformation of CPI-613 occurred rapidly following infusion, with CPI-2850 becoming the major circulating species in plasma over time.
3 In order to gain insight into the genetic features associated with the complete responses to the combined treatment by CPI-361 and FOLFIRINOX, tumor tissues and matching peripheral blood samples from three available exceptional responsive patients, CPI-ER1, CPI-ER2, and CPI-ER3, were obtained from Wake Forest Baptist Comprehensive Cancer Center Tumor Tissue Bank. Genomic DNAs were isolated and subjected to whole exome DNA sequencing (75x75 bp paired ends) on an Illumina NextSeq 500 using the Illumina TruSeq Rapid Exome Library prep kit. Tumor DNA samples were sequenced to an average depth of 300X and the matching normal DNA samples were sequenced to an average of 50X.
The raw fastq files were generated by four different lanes using the illumina TruSeq Rapid Exome Library. For each fastq file, it was aligned to reference (hg19) by BWA mem, 12 with version bwa-0.7.12. The preprocessing for somatic mutation calling includes duplicate mark by Picard (https://broadinstitute.github.io/picard/), indel realignment by GATK 3.6 (https://software.broadinstitute.org/gatk/), and base recalibration by GATK 3.6. This preprocessing was implemented for each sam output from BWA. For each sample, the four aligned bam files were merged as the final bam by Samtools 1.3.1, 13 after adding read group (RG) information into each aligned bam file during preprocessing. The somatic mutation calling was implemented by MuTect1-1.1.4, 14 VarScan2 -2.3.9, 15 and Somatic-SNIPER. 16 The somatic mutation loci and genes for each sample were combined from the outputs of the three pipelines for somatic mutation calling. To specify the tumor purity for the VarScan2, we utilized AbsCN-seq software. 17 The estimated tumor purities were compared with those from pathologists ( Table 2) . Using the above three pipelines for somatic mutation calling, we identified 219, 1,999, and 135 somatically mutated genes in samples of CPI-ER1, CPI-ER2, and CPI-ER3, respectively. The mutation rates were comparable with those reported PDAC cohorts ( Table 3) . Mutations in KRAS, TP53, and SMAD4 genes are known to be commonly mutated in PDACs in most published cohorts including TCGA, 18 ICGC, 19 paad_utsw_2015, 20 and paad_qcmg_uq_2016. 21 In our three responders, KRAS mutations were found in all three cases and TP53 mutations were found in two cases. Interestingly, SMAD4 mutation was not found in any of the three responders. In addition, our analysis revealed frequent mutations in the members of mucin gene family including MUC4, MUC12, MUC17, MUC20, MUC22, and MUC5B (Tables 4). Whereas mucin genes have been found to be mutated in PDACs, the frequencies are much lower than what we found in the three responders to CPI-613 and FOLFIRINOX ( Table 4) . SMAD3/SMAD4 has been shown to act as a transcriptional factor for MUC4, which is regulated by TGF signaling. Therefore, MUC gene mutations may represent a common defect in the TGFpathway in a subset of PDACs and this alteration may result in a vulnerability to the combination treatment targeting genome and mitochondria-associated metabolism. Consistent with this hypothesis, some MUC family members have been shown to locate to the mitochondria 22 and be regulated by hypoxia. 23 Future functional studies are needed to shed light on this potentially important mechanism of targeted therapeutics for PDACs. *Source data were downloaded from cBioPortal and the mutations are validated.
Comparison with FOLFIRINOX alone at our institution
We sought and obtained IRB exemption to perform the search. We queried the hospital Electronic Medical Record Epic's Clarity Relational Database for primary diagnosis codes of malignant neoplasm of pancreas (ICD-10 C25 and ICD-9 157) between January 1, 2012 and December 1, 2016. There were 1145 patients matching the criteria. Then, we queried Epic to identify how many of those 1145 patients received FLUOROURACIL and the result was 90 patients. Next, we excluded 25 patients who received CPI-613 for this study (CCWFU 57112) or for compassionate use. For the remaining 65 patients, Irinotecan and Oxaliplatin administration dates and doses, vitals, last contact, race, and ethnicity were retrieved from Epic. The Cancer Registry has been utilized for staging and previous treatments for those patients including surgery, radiation therapy etc. In order to validate and complete the data that had been extracted from Epic and the Cancer Registry, we performed a chart review of 65 patients and excluded patients who would not have met criteria such as non-stage IV, neoadjuvant therapy etc. 6 patients were excluded due to pancreatic adenocarcinoma not being the primary diagnosis. 29 patients were not diagnosed with stage IV disease at presentation. 8 patients were excluded because they were not treated with FOLFIRINOX in the front line setting. 22 patients have been identified and validated with stage IV pancreatic adenocarcinoma at diagnosis and who were treated with FOLFIRINOX in the first line setting. In addition, we documented their ECOG performance status at diagnosis, date of diagnosis, and treatment response. Each patient's chart was independently reviewed by two different physicians to ensure the accuracy of the reported findings ( Figure 4 ). 
